WO2020014471A1 - Methods and compositions for delivery of agents across the blood-brain barrier - Google Patents
Methods and compositions for delivery of agents across the blood-brain barrier Download PDFInfo
- Publication number
- WO2020014471A1 WO2020014471A1 PCT/US2019/041386 US2019041386W WO2020014471A1 WO 2020014471 A1 WO2020014471 A1 WO 2020014471A1 US 2019041386 W US2019041386 W US 2019041386W WO 2020014471 A1 WO2020014471 A1 WO 2020014471A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- aav
- capsid protein
- sequence
- aav9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0097—Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the AAV capsid protein comprises a targeting sequence that comprises at least six contiguous amino acids from the sequence TVSALK (SEQ ID NO:4); TVSALFK (SEQ ID NO:8); KLASVT (SEQ ID NO:83); or KFLASVT (SEQ ID NO:84).
- nucleic acids encoding the AAV capsid proteins comprising a targeting sequence as described herein.
- Adeno-associated virus has emerged as an important research and clinical tool for delivering therapeutic genes to the brain, spinal cord and the eye; see, e.g., US9102949; US 9585971; and US20170166926.
- existing AAVs including AAV9 have either limited efficiency in crossing the BBB, or only work in some non-primate species.
- X 6 is K, R, H, D, or E (SEQ ID NO: 74).
- X3, X4, X5, Xe are any four non-identical amino acids of V, A, L, I, G, P, S, T, or M;
- X 2 , X3, X4, X5 are any four non-identical amino acids of V, A, L, I, G, P, S, T, or M;
- the targeting peptides comprise a sequence of Xi X 2 X3 X 4 X5 Xe X7, wherein:
- AAV that include one or more of the targeting peptide sequences described herein, e.g., an AAV comprising a capsid protein comprising a targeting sequence described herein, e.g., a capsid protein comprising SEQ ID NO: 1 wherein a targeting peptide sequence has been inserted into the sequence, e.g., between amino acids 588 and 589.
- HEK293T cells were cultured at 37 °C in a 5% C02 incubator.
- a cDNA plasmid of LY6A was transiently transfected into the cells using a transfection mixture of 200ul DMEM (31053028; Gibco), 1 ug DNA plasmid and 3ug of PEI.
- DMEM 31053028; Gibco
- PEI 1 ug DNA plasmid
- PEI PEI
- AAV.CPP.16 and AAV.CPP.21 also showed enhanced ability vs. AAV9 in targeting the spinal cord and motor neurons in mice. All AAVs carry nuclear RFP as reporter and were administered intravenously into neonate mice (4 x 10 10 vg). Motor neurons were visualized using CHAT antibody staining. Co-localization of RFP and CHAT signals in FIG. 8B suggested specific transduction of the motor neurons.
- AAVs-CAG-AADC (as reporter gene) were injected intravenously into 3 -month-old cynomolgus monkeys.
- AAV-transduced cells (shown in black) were visualized using antibody staining against AADC.
- FIGs. 10A-D AAV.CPP.16 and AAV.CPP.21 showed enhanced ability vs. AAV9 to transduce brain cells after intravenous administration in non-human primates.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19833958.2A EP3820885A4 (en) | 2018-07-11 | 2019-07-11 | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF DRUGS ACROSS THE BLOOD-BRAIN BARRIER |
| CA3105381A CA3105381A1 (en) | 2018-07-11 | 2019-07-11 | Methods and compositions for delivery of agents across the blood-brain barrier |
| CN201980059342.1A CN112703198B (zh) | 2018-07-11 | 2019-07-11 | 用于跨血脑屏障递送试剂的方法和组合物 |
| CN202510648887.3A CN120843603A (zh) | 2018-07-11 | 2019-07-11 | 用于跨血脑屏障递送试剂的方法和组合物 |
| JP2021500538A JP2021530218A (ja) | 2018-07-11 | 2019-07-11 | 血液脳関門を超える薬剤の送達のための方法および組成物 |
| US17/258,846 US12398181B2 (en) | 2018-07-11 | 2019-07-11 | Methods and compositions for delivery of agents across the blood-brain barrier |
| US17/457,337 US11518787B2 (en) | 2018-07-11 | 2021-12-02 | Methods and compositions for delivery of agents across the blood-brain barrier |
| US18/048,716 US20230077490A1 (en) | 2018-07-11 | 2022-10-21 | Methods and compositions for delivery of agents across the blood-brain barrier |
| JP2024092463A JP7897894B2 (ja) | 2018-07-11 | 2024-06-06 | 血液脳関門を超える薬剤の送達のための方法および組成物 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696422P | 2018-07-11 | 2018-07-11 | |
| US62/696,422 | 2018-07-11 |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/258,846 A-371-Of-International US12398181B2 (en) | 2018-07-11 | 2019-07-11 | Methods and compositions for delivery of agents across the blood-brain barrier |
| US17/457,337 Continuation US11518787B2 (en) | 2018-07-11 | 2021-12-02 | Methods and compositions for delivery of agents across the blood-brain barrier |
| US18/048,716 Continuation US20230077490A1 (en) | 2018-07-11 | 2022-10-21 | Methods and compositions for delivery of agents across the blood-brain barrier |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2020014471A1 true WO2020014471A1 (en) | 2020-01-16 |
Family
ID=69142796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2019/041386 Ceased WO2020014471A1 (en) | 2018-07-11 | 2019-07-11 | Methods and compositions for delivery of agents across the blood-brain barrier |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US12398181B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3820885A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021530218A (cg-RX-API-DMAC7.html) |
| CN (2) | CN112703198B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3105381A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020014471A1 (cg-RX-API-DMAC7.html) |
Cited By (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020160337A1 (en) * | 2019-01-30 | 2020-08-06 | The Broad Institute, Inc. | Systems for evolved adeno-associated viruses (aavs) for targeted delivery |
| WO2021230987A1 (en) * | 2020-05-13 | 2021-11-18 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
| WO2022067935A1 (zh) * | 2020-09-30 | 2022-04-07 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
| WO2022232327A3 (en) * | 2021-04-27 | 2022-11-24 | The General Hospital Corporation | Aav capsids and uses thereof |
| US20230048492A1 (en) * | 2021-06-21 | 2023-02-16 | The Brigham And Women`S Hospital, Inc. | Adeno-Associated Viral (AAV) Vectors for Tissue-Targeted Expression of Therapeutic Genes |
| WO2023081648A1 (en) * | 2021-11-02 | 2023-05-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| US11759531B2 (en) | 2020-02-13 | 2023-09-19 | Tenaya Therapeutics, Inc. | Gene therapy vectors for treating heart disease |
| US20230346981A1 (en) * | 2019-11-22 | 2023-11-02 | The Children's Hospital Of Philadelphia | Adeno-associated viral vector variants |
| WO2023240236A1 (en) * | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| US11981705B2 (en) | 2020-01-10 | 2024-05-14 | The Brigham And Women's Hospital, Inc. | Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer |
| US12054724B2 (en) | 2018-04-10 | 2024-08-06 | President And Fellows Of Harvard College | AAV vectors encoding clarin-1 or GJB2 and uses thereof |
| WO2024191778A1 (en) | 2023-03-10 | 2024-09-19 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| JP2024536278A (ja) * | 2021-10-01 | 2024-10-04 | ナイベック カンパニー リミテッド | 血液脳関門透過用ペプチド及びこの用途 |
| US12116385B2 (en) | 2021-10-08 | 2024-10-15 | Dyno Therapeutics, Inc. | Capsid variants and methods of using the same |
| US12129287B2 (en) | 2020-09-14 | 2024-10-29 | President And Fellows Of Harvard College | Recombinant adeno associated virus encoding clarin-1 and uses thereof |
| WO2025004001A1 (en) | 2023-06-30 | 2025-01-02 | Takeda Pharmaceutical Company Limited | Htt repressors and uses thereof |
| EP4199972A4 (en) * | 2020-08-21 | 2025-01-15 | Capsida, Inc. | ADENO-ASSOCIATED VIRUS COMPOSITIONS WITH PREFERRED EXPRESSION LEVELS |
| WO2025049993A1 (en) | 2023-08-31 | 2025-03-06 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2025096967A1 (en) * | 2023-11-02 | 2025-05-08 | Biogen Ma Inc. | Redirection of aav capsids for central nervous system targeting |
| CN120230754A (zh) * | 2025-03-28 | 2025-07-01 | 贵州医科大学 | 一种基因、融合蛋白、重组载体、重组细胞、脑靶向外泌体及其应用 |
| WO2025171227A1 (en) | 2024-02-08 | 2025-08-14 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| US12398181B2 (en) | 2018-07-11 | 2025-08-26 | The Brigham And Women's Hospital, Inc. | Methods and compositions for delivery of agents across the blood-brain barrier |
| US12467046B2 (en) | 2018-10-02 | 2025-11-11 | Voyager Therapeutics, Inc. | Redirection of tropism of AAV capsids |
| WO2026064442A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| US12637692B2 (en) | 2020-04-29 | 2026-05-26 | The Broad Institute, Inc. | Machine learning accelerated protein engineering through fitness prediction |
| WO2026122963A1 (en) | 2024-12-06 | 2026-06-11 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114606264B (zh) * | 2022-03-22 | 2025-08-26 | 三峡大学 | 一种用于神经系统药物递送的aav病毒载体 |
| WO2024229777A1 (zh) * | 2023-05-11 | 2024-11-14 | 深圳先进技术研究院 | 一种aav载体及其应用 |
| WO2024249810A2 (en) * | 2023-06-02 | 2024-12-05 | The Brigham And Women's Hospital, Inc. | Combinatory use of adeno-associated viruses and focused ultrasound for overcoming the blood-brain barrier |
| CN116808231B (zh) * | 2023-07-07 | 2024-03-26 | 中国药科大学 | 一种细胞穿膜肽偶联舒必利前药体系以及制备方法和应用 |
| CN117964715B (zh) * | 2023-07-21 | 2025-01-24 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
| WO2025076091A1 (en) * | 2023-10-03 | 2025-04-10 | Brave Bio, Inc. | Cd20 antibody aav vectors and methods of use thereof |
| WO2025231400A1 (en) | 2024-05-03 | 2025-11-06 | Sangamo Therapeutics, Inc. | Synthetic transcription factors and methods of making and using thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030082143A1 (en) * | 1997-08-29 | 2003-05-01 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
| US20150297742A1 (en) * | 2012-12-05 | 2015-10-22 | Ruprecht-Karls-Universitat | Conjugates of Proteins and Multivalent Cell-Penetrating Peptides and Their Uses |
| US20160280748A1 (en) * | 2009-04-28 | 2016-09-29 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
| US20160376325A1 (en) * | 2014-03-11 | 2016-12-29 | University Of Florida Research Foundation, Inc. | Use of aav-expressed m013 protein as an anti-inflammatory therapeutic |
| US20170130245A1 (en) * | 2014-06-09 | 2017-05-11 | Voyager Therapeutics, Inc. | Chimeric capsids |
| US20180030429A1 (en) * | 2015-02-27 | 2018-02-01 | University Of Washington | Polypeptide Assemblies and Methods for the Production Thereof |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| DE60035057T2 (de) | 1999-10-04 | 2008-01-31 | Novartis Vaccines and Diagnostics, Inc., Emeryville | CD40 Antagonist zur Behandlung von Psoriasis |
| US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| CA2658221C (en) | 2001-04-27 | 2012-11-27 | Kyowa Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| EP1707627B1 (en) | 2003-12-25 | 2012-11-14 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic anti-CD40 antibody mutant |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| SMP200800064B (it) | 2006-04-21 | 2009-11-06 | Novartis Ag | Composizioni farmaceutiche di anticorpi anti-cd40 antagonista |
| CA2693712C (en) | 2007-07-14 | 2018-05-29 | The University Of Iowa Research Foundation | Methods and compositions for treating brain diseases |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
| EP2796467B1 (en) | 2010-03-31 | 2018-03-28 | Boehringer Ingelheim International GmbH | Anti-CD40 antibodies |
| DK2561073T3 (en) * | 2010-04-23 | 2016-12-12 | Univ Massachusetts | Aav vectors targeted to central nervous system and methods of use thereof |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| EP3702460A1 (en) | 2010-11-12 | 2020-09-02 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| AU2011349464B2 (en) | 2010-12-20 | 2016-07-07 | The General Hospital Corporation | Polycomb-associated non-coding RNAS |
| ES2734076T3 (es) | 2011-02-17 | 2019-12-04 | Kyowa Hakko Kirin Co Ltd | Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada |
| DK3693025T3 (da) | 2011-04-22 | 2022-01-10 | Univ California | Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf |
| KR102037432B1 (ko) | 2011-04-29 | 2019-11-27 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| PL2900686T3 (pl) | 2012-09-28 | 2021-01-25 | The University Of North Carolina At Chapel Hill | Wektory aav ukierunkowane na oligodendrocyty |
| AU2013332061A1 (en) | 2012-10-17 | 2015-05-07 | Fondazione Telethon | Gene therapy for glycogen storage diseases |
| CA2888763A1 (en) | 2012-10-30 | 2014-05-08 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| KR102298579B1 (ko) | 2013-05-21 | 2021-09-07 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 캡시드-변형된 raav3 벡터 조성물, 및 인간 간암의 유전자 요법에서의 용도 |
| AU2014276440A1 (en) | 2013-06-03 | 2015-11-05 | Novartis Ag | Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor |
| EP3564379A1 (en) * | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| WO2015060722A1 (en) | 2013-10-24 | 2015-04-30 | Uniqure Ip B.V. | Aav-5 pseudotyped vector for gene therapy for neurological diseases |
| US11053291B2 (en) * | 2014-02-19 | 2021-07-06 | University Of Florida Research Foundation, Incorporated | Delivery of Nrf2 as therapy for protection against reactive oxygen species |
| CN106604933B (zh) | 2014-07-11 | 2021-08-10 | 文塔纳医疗系统公司 | 抗pd-l1抗体及其诊断用途 |
| US10370432B2 (en) | 2014-10-03 | 2019-08-06 | University Of Massachusetts | Heterologous targeting peptide grafted AAVS |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| CA3172682A1 (en) | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| CN104965364B (zh) | 2015-07-14 | 2018-03-30 | 武汉华星光电技术有限公司 | 阵列基板及驱动阵列基板的方法 |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| EP3373979A1 (en) | 2015-11-12 | 2018-09-19 | Pfizer Inc | Tissue-specific genome engineering using crispr-cas9 |
| AU2016366549B2 (en) * | 2015-12-11 | 2022-11-10 | California Institute Of Technology | Targeting peptides for directing adeno-associated viruses (AAVs) |
| CN106939047B (zh) | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| CA3011939A1 (en) | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
| EP3583220A4 (en) | 2017-02-15 | 2021-07-07 | The University of North Carolina at Chapel Hill | PROCEDURES AND COMPOSITIONS FOR GENERAL TRANSFER IN THE VASCULAR SYSTEM |
| WO2019012176A1 (en) | 2017-07-11 | 2019-01-17 | Outotec (Finland) Oy | WATERING APPARATUS |
| US11512327B2 (en) | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
| JP7403165B2 (ja) | 2017-12-19 | 2023-12-22 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 血液脳関門を通過してウイルスベクターを送達するための方法および組成物 |
| WO2019222329A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| US20210207167A1 (en) | 2018-05-16 | 2021-07-08 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
| SG11202012203PA (en) | 2018-06-27 | 2021-01-28 | Precigen Inc | In vivo controlled combination therapy for treatment of cancer |
| AU2019299555A1 (en) | 2018-07-04 | 2021-02-25 | Cytoimmune Therapeutics, Inc. | Compositions and methods for immunotherapy targeting FLT3, PD-1, and/or PD-L1 |
| JP2021530218A (ja) | 2018-07-11 | 2021-11-11 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 血液脳関門を超える薬剤の送達のための方法および組成物 |
| EP3830107A2 (en) | 2018-08-03 | 2021-06-09 | Voyager Therapeutics, Inc. | Aav variants with enhanced tropism |
| US11149256B2 (en) | 2018-09-26 | 2021-10-19 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
| CN113166208B (zh) | 2018-10-02 | 2024-11-22 | 沃雅戈治疗公司 | 重新定向aav衣壳的嗜性 |
| US20210371470A1 (en) | 2018-10-12 | 2021-12-02 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| AU2020214831B2 (en) | 2019-01-30 | 2025-09-25 | The Broad Institute, Inc. | Systems for evolved adeno-associated viruses (AAVs) for targeted delivery |
| SG11202111249YA (en) | 2019-04-11 | 2021-11-29 | California Inst Of Techn | Virus compositions with enhanced specificity in the brain |
| US20230075314A1 (en) | 2019-04-29 | 2023-03-09 | Voyager Therapeutics, Inc. | VECTORIZED ANTIBODIES (vAb) AND USES THEREOF |
| WO2021025995A1 (en) | 2019-08-02 | 2021-02-11 | Voyager Therapeutics, Inc. | Aav variants with enhanced tropism |
| CA3167290A1 (en) | 2020-01-10 | 2021-07-15 | The Brigham And Women's Hospital, Inc. | Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer |
| WO2022272240A2 (en) | 2021-06-21 | 2022-12-29 | The Brigham And Women’S Hospital, Inc. | Adeno-associated viral (aav) vectors for tissue-targeted expression of therapeutic genes |
-
2019
- 2019-07-11 JP JP2021500538A patent/JP2021530218A/ja not_active Withdrawn
- 2019-07-11 CA CA3105381A patent/CA3105381A1/en active Pending
- 2019-07-11 CN CN201980059342.1A patent/CN112703198B/zh active Active
- 2019-07-11 WO PCT/US2019/041386 patent/WO2020014471A1/en not_active Ceased
- 2019-07-11 EP EP19833958.2A patent/EP3820885A4/en active Pending
- 2019-07-11 CN CN202510648887.3A patent/CN120843603A/zh active Pending
- 2019-07-11 US US17/258,846 patent/US12398181B2/en active Active
-
2021
- 2021-12-02 US US17/457,337 patent/US11518787B2/en active Active
-
2022
- 2022-10-21 US US18/048,716 patent/US20230077490A1/en active Pending
-
2024
- 2024-06-06 JP JP2024092463A patent/JP7897894B2/ja active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030082143A1 (en) * | 1997-08-29 | 2003-05-01 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
| US20160280748A1 (en) * | 2009-04-28 | 2016-09-29 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
| US20150297742A1 (en) * | 2012-12-05 | 2015-10-22 | Ruprecht-Karls-Universitat | Conjugates of Proteins and Multivalent Cell-Penetrating Peptides and Their Uses |
| US20160376325A1 (en) * | 2014-03-11 | 2016-12-29 | University Of Florida Research Foundation, Inc. | Use of aav-expressed m013 protein as an anti-inflammatory therapeutic |
| US20170130245A1 (en) * | 2014-06-09 | 2017-05-11 | Voyager Therapeutics, Inc. | Chimeric capsids |
| US20180030429A1 (en) * | 2015-02-27 | 2018-02-01 | University Of Washington | Polypeptide Assemblies and Methods for the Production Thereof |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP3820885A4 * |
Cited By (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12054724B2 (en) | 2018-04-10 | 2024-08-06 | President And Fellows Of Harvard College | AAV vectors encoding clarin-1 or GJB2 and uses thereof |
| US12398181B2 (en) | 2018-07-11 | 2025-08-26 | The Brigham And Women's Hospital, Inc. | Methods and compositions for delivery of agents across the blood-brain barrier |
| US12467046B2 (en) | 2018-10-02 | 2025-11-11 | Voyager Therapeutics, Inc. | Redirection of tropism of AAV capsids |
| WO2020160337A1 (en) * | 2019-01-30 | 2020-08-06 | The Broad Institute, Inc. | Systems for evolved adeno-associated viruses (aavs) for targeted delivery |
| US20230346981A1 (en) * | 2019-11-22 | 2023-11-02 | The Children's Hospital Of Philadelphia | Adeno-associated viral vector variants |
| US12653910B2 (en) * | 2019-11-22 | 2026-06-16 | The Children's Hospital Of Philadelphia | Adeno-associated viral vector variants |
| US11981705B2 (en) | 2020-01-10 | 2024-05-14 | The Brigham And Women's Hospital, Inc. | Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer |
| US11759531B2 (en) | 2020-02-13 | 2023-09-19 | Tenaya Therapeutics, Inc. | Gene therapy vectors for treating heart disease |
| US12478691B2 (en) | 2020-02-13 | 2025-11-25 | Tenaya Therapeutics, Inc. | Gene therapy vectors for treating heart disease |
| US12637692B2 (en) | 2020-04-29 | 2026-05-26 | The Broad Institute, Inc. | Machine learning accelerated protein engineering through fitness prediction |
| US12577588B2 (en) | 2020-05-13 | 2026-03-17 | Voyager Therapeutics, Inc. | AAV capsids with increased tropism to brain tissue |
| US11859200B2 (en) | 2020-05-13 | 2024-01-02 | Voyager Therapeutics, Inc. | AAV capsids with increased tropism to brain tissue |
| US12630842B2 (en) | 2020-05-13 | 2026-05-19 | Voyager Therapeutics, Inc. | Redirection of tropism of AAV capsids |
| WO2021230987A1 (en) * | 2020-05-13 | 2021-11-18 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
| US20220042044A1 (en) * | 2020-05-13 | 2022-02-10 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
| CN116096734A (zh) * | 2020-05-13 | 2023-05-09 | 沃雅戈治疗公司 | Aav衣壳的向性的重定向 |
| EP4199972A4 (en) * | 2020-08-21 | 2025-01-15 | Capsida, Inc. | ADENO-ASSOCIATED VIRUS COMPOSITIONS WITH PREFERRED EXPRESSION LEVELS |
| US12129287B2 (en) | 2020-09-14 | 2024-10-29 | President And Fellows Of Harvard College | Recombinant adeno associated virus encoding clarin-1 and uses thereof |
| WO2022067935A1 (zh) * | 2020-09-30 | 2022-04-07 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
| WO2022232327A3 (en) * | 2021-04-27 | 2022-11-24 | The General Hospital Corporation | Aav capsids and uses thereof |
| EP4359519A4 (en) * | 2021-06-21 | 2025-11-26 | Brigham & Womens Hospital Inc | Adeno-associated viral (AAV) vectors for targeted tissue expression of therapeutic genes |
| US20230048492A1 (en) * | 2021-06-21 | 2023-02-16 | The Brigham And Women`S Hospital, Inc. | Adeno-Associated Viral (AAV) Vectors for Tissue-Targeted Expression of Therapeutic Genes |
| WO2022272240A3 (en) * | 2021-06-21 | 2023-02-23 | The Brigham And Women's Hospital, Inc. | Adeno-associated viral (aav) vectors for tissue-targeted expression of therapeutic genes |
| JP2024536278A (ja) * | 2021-10-01 | 2024-10-04 | ナイベック カンパニー リミテッド | 血液脳関門透過用ペプチド及びこの用途 |
| US12528841B2 (en) | 2021-10-08 | 2026-01-20 | Dyno Therapeutics, Inc. | Capsid variants and methods of using the same |
| US12331081B2 (en) | 2021-10-08 | 2025-06-17 | Dyno Therapeutics, Inc. | Capsid variants and methods of using the same |
| US12655180B2 (en) | 2021-10-08 | 2026-06-16 | Dyno Therapeutics, Inc. | Capsid variants and methods of using the same |
| US12116385B2 (en) | 2021-10-08 | 2024-10-15 | Dyno Therapeutics, Inc. | Capsid variants and methods of using the same |
| US12331082B2 (en) | 2021-10-08 | 2025-06-17 | Dyno Therapeutics, Inc. | Capsid variants and methods of using the same |
| US12296025B2 (en) | 2021-11-02 | 2025-05-13 | Voyager Therapeutics, Inc. | AAV capsid variants and uses thereof |
| WO2023081648A1 (en) * | 2021-11-02 | 2023-05-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| US12419969B2 (en) | 2021-11-02 | 2025-09-23 | Voyager Therapeutics, Inc. | AAV capsid variants and uses thereof |
| WO2023240236A1 (en) * | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| WO2024191778A1 (en) | 2023-03-10 | 2024-09-19 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2025004001A1 (en) | 2023-06-30 | 2025-01-02 | Takeda Pharmaceutical Company Limited | Htt repressors and uses thereof |
| WO2025049993A1 (en) | 2023-08-31 | 2025-03-06 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2025096967A1 (en) * | 2023-11-02 | 2025-05-08 | Biogen Ma Inc. | Redirection of aav capsids for central nervous system targeting |
| WO2025171227A1 (en) | 2024-02-08 | 2025-08-14 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026064442A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026122963A1 (en) | 2024-12-06 | 2026-06-11 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| CN120230754A (zh) * | 2025-03-28 | 2025-07-01 | 贵州医科大学 | 一种基因、融合蛋白、重组载体、重组细胞、脑靶向外泌体及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024129031A (ja) | 2024-09-26 |
| US20230077490A1 (en) | 2023-03-16 |
| US11518787B2 (en) | 2022-12-06 |
| CA3105381A1 (en) | 2020-01-16 |
| EP3820885A1 (en) | 2021-05-19 |
| JP7897894B2 (ja) | 2026-07-30 |
| CN120843603A (zh) | 2025-10-28 |
| US20210277066A1 (en) | 2021-09-09 |
| US20220089650A1 (en) | 2022-03-24 |
| US12398181B2 (en) | 2025-08-26 |
| JP2021530218A (ja) | 2021-11-11 |
| CN112703198B (zh) | 2025-05-30 |
| CN112703198A (zh) | 2021-04-23 |
| EP3820885A4 (en) | 2022-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11518787B2 (en) | Methods and compositions for delivery of agents across the blood-brain barrier | |
| US20240209394A1 (en) | AAV Capsids and Uses Thereof | |
| JP7659271B2 (ja) | 導入遺伝子発現のための操作されたアデノ随伴(aav)ベクター | |
| CN114127089A (zh) | 重组腺相关病毒及其用途 | |
| US20250074949A1 (en) | Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer | |
| JP2023515795A (ja) | Aavカプシド-プロモーター相互作用および細胞選択的遺伝子発現 | |
| US20230048492A1 (en) | Adeno-Associated Viral (AAV) Vectors for Tissue-Targeted Expression of Therapeutic Genes | |
| KR20250114282A (ko) | 근육 특이적 조절 카세트 | |
| JP2023545384A (ja) | 中枢神経系または筋肉送達のための組換えアデノ随伴ウイルス | |
| WO2024216244A9 (en) | Targeting aav capsids, methods of manufacturing and using same | |
| EP4698554A2 (en) | Aav capsids for on-target delivery to spinal cord | |
| CN117396213A (zh) | 用于癌症治疗的脱氧核糖核酸酶与细胞疗法的组合 | |
| CA3092451A1 (en) | A modular system for gene and protein delivery based on aav |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19833958 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 3105381 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 2021500538 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2019833958 Country of ref document: EP Effective date: 20210211 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 201980059342.1 Country of ref document: CN |
|
| WWG | Wipo information: grant in national office |
Ref document number: 17258846 Country of ref document: US |